By: IPP Bureau
Last updated : January 25, 2025 11:27 am
Q3 FY25 revenue up 24% to Rs 3,230 crore
Mankind Pharma, India’s fourth largest pharmaceutical company, announced its financial results for the third quarter and nine months ended 31st December 2024.
The company reported revenue from operations at Rs. 3,230 crore, up by 24% YoY and domestic revenue at Rs. 2,773 crore, up 17%, Exports at Rs. 457 crore, up 121% YoY. The company’s adjusted EBITDA margin of 27.7% up by 430 bps YoY and PAT margin of 11.9%.
“We achieved a healthy revenue growth of 24% YoY with strong adjusted EBITDA margin of 27.7% in Q3FY25, driven by continued outperformance in Chronic, strong recovery in OTC and consolidation of BSV. 30% YoY revenue growth in OTC business supported by strategic initiatives undertaken last year. The integration of BSV is on track, with focus on mandate brands, improving productivity and adopting best practices to ensure long term sustainable growth,” Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma said.
He also maintained that 2024 has been a transformative year – now having multiple building blocks – steady base business, fast growing specialty chronic segment, high potential OTC business, and high-entry barrier super specialty portfolio of BSV.